Subtopic Deep Dive
GATA3 as Prognostic Marker in Metastatic Carcinoma
Research Guide
What is GATA3 as Prognostic Marker in Metastatic Carcinoma?
GATA3 serves as an immunohistochemical prognostic marker in metastatic carcinomas, particularly breast cancer, where its expression correlates with survival outcomes and metastasis patterns.
GATA3 expression is evaluated via immunohistochemistry in metastatic breast and other carcinomas to assess prognostic value (Liu et al., 2012, 299 citations). Studies link high GATA3 levels to hormone receptor status and better prognosis in certain subtypes (Albergaria et al., 2009, 158 citations). Over 10 papers from 2008-2022 examine its role, with Hennessy et al. (2009, 853 citations) characterizing GATA3 in aggressive metaplastic breast cancers.
Why It Matters
GATA3 immunohistochemistry stratifies metastatic breast cancer patients for risk assessment, guiding personalized therapies in hormone receptor-negative tumors (Albergaria et al., 2009). Liu et al. (2012) showed GATA3 positivity in 92% of breast carcinomas versus lower rates in other metastases, aiding differential diagnosis. Theodorou et al. (2013) demonstrated GATA3 shapes ESR1 binding enhancers, influencing therapeutic responses in metastatic disease (Park et al., 2022). This marker improves survival predictions in clinical trials.
Key Research Challenges
Heterogeneous GATA3 Expression
GATA3 shows variable expression across carcinoma subtypes, complicating prognostic interpretations (Liu et al., 2012). Hennessy et al. (2009) noted low GATA3 in metaplastic breast cancers with EMT features. Standardization of IHC scoring remains inconsistent.
Correlation with Survival Outcomes
Linking GATA3 status to metastasis-free survival requires large cohorts (Albergaria et al., 2009). Studies like Park et al. (2022) highlight needs for multivariate analyses including therapy responses. Confounding factors like ER status obscure independent prognostic value.
Limited Non-Breast Applications
GATA3 utility in non-breast metastatic carcinomas is underexplored despite expression in urothelial tumors (Liu et al., 2012). Few papers address cross-carcinoma comparisons. Validation in diverse metastatic sites is needed.
Essential Papers
Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
Bryan T. Hennessy, Ana-Maria Gonzalez-Angulo, Katherine Stemke‐Hale et al. · 2009 · Cancer Research · 853 citations
Abstract Metaplastic breast cancers (MBC) are aggressive, chemoresistant tumors characterized by lineage plasticity. To advance understanding of their pathogenesis and relatedness to other breast c...
GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility
Vassiliki Theodorou, Rory Stark, Suraj Menon et al. · 2012 · Genome Research · 375 citations
Estrogen receptor (ESR1) drives growth in the majority of human breast cancers by binding to regulatory elements and inducing transcription events that promote tumor growth. Differences in enhancer...
Breast Cancer Metastasis: Mechanisms and Therapeutic Implications
Misung Park, Do‐Hee Kim, Sunghyub Ko et al. · 2022 · International Journal of Molecular Sciences · 340 citations
Breast cancer is the most common malignancy in women worldwide. Metastasis is the leading cause of high mortality in most cancers. Although predicting the early stage of breast cancer before metast...
Immunohistochemical Evaluation of GATA3 Expression in Tumors and Normal Tissues
Haiyan Liu, Jianhui Shi, Myra L. Wilkerson et al. · 2012 · American Journal of Clinical Pathology · 299 citations
Abstract GATA3 expression has been reported in urothelial and breast carcinomas; however, the published data on GATA3 expression in tumors from other organs are limited. Immunohistochemical evaluat...
TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer
Di Ai, Jun Yao, Fei Yang et al. · 2020 · Modern Pathology · 187 citations
Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate
Howard Kendrick, Joseph L. Regan, Fiona‐Ann Magnay et al. · 2008 · BMC Genomics · 180 citations
Abstract Background Understanding the molecular control of cell lineages and fate determination in complex tissues is key to not only understanding the developmental biology and cellular homeostasi...
Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours
André Albergaria, Joana Paredes, Bárbara Sousa et al. · 2009 · Breast Cancer Research · 158 citations
Abstract Introduction The expression of additional genes, other than oestrogen receptor (ER), may be important to the hormone-responsive phenotype of breast cancer. Microarray analyses have reveale...
Reading Guide
Foundational Papers
Start with Liu et al. (2012, 299 citations) for IHC expression across tumors, then Hennessy et al. (2009, 853 citations) for GATA3 in aggressive subtypes, and Albergaria et al. (2009) for prognostic data in ER-negative cases.
Recent Advances
Study Park et al. (2022, 340 citations) for metastasis mechanisms and Ai et al. (2020, 187 citations) for TRPS1 comparisons in triple-negative breast cancer.
Core Methods
Core techniques include immunohistochemistry (Liu et al., 2012), transcriptome profiling (Kendrick et al., 2008), and enhancer accessibility assays (Theodorou et al., 2012).
How PapersFlow Helps You Research GATA3 as Prognostic Marker in Metastatic Carcinoma
Discover & Search
Research Agent uses searchPapers('GATA3 prognostic metastatic carcinoma') to retrieve Liu et al. (2012, 299 citations), then citationGraph reveals citing works like Ai et al. (2020), and findSimilarPapers expands to Hennessy et al. (2009, 853 citations) for EMT context.
Analyze & Verify
Analysis Agent applies readPaperContent on Albergaria et al. (2009) to extract survival data, verifyResponse with CoVe checks GATA3-ER correlations against Theodorou et al. (2012), and runPythonAnalysis performs Kaplan-Meier survival curve plotting from reported hazard ratios with GRADE grading for evidence strength.
Synthesize & Write
Synthesis Agent detects gaps in non-breast carcinoma applications via contradiction flagging across Liu et al. (2012) and Park et al. (2022), while Writing Agent uses latexEditText for prognostic model sections, latexSyncCitations for 10+ references, and latexCompile to generate a review manuscript with exportMermaid for GATA3 signaling diagrams.
Use Cases
"Extract survival data from GATA3 IHC studies in breast metastasis and plot hazard ratios."
Research Agent → searchPapers → Analysis Agent → readPaperContent(Albergaria et al., 2009) → runPythonAnalysis(pandas survival curves, matplotlib plots) → researcher gets CSV-exported Kaplan-Meier figures with p-values.
"Draft LaTeX review on GATA3 as marker in metastatic carcinoma."
Synthesis Agent → gap detection → Writing Agent → latexEditText(intro/methods) → latexSyncCitations(Hennessy 2009, Liu 2012) → latexCompile → researcher gets compiled PDF with figure tables.
"Find code for GATA3 expression analysis in breast cancer papers."
Research Agent → searchPapers → Code Discovery (paperExtractUrls → paperFindGithubRepo → githubRepoInspect) on Kendrick et al. (2008) transcriptome data → researcher gets R scripts for lineage analysis with usage examples.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'GATA3 metastatic carcinoma prognosis', structures report with GRADE-scored evidence from Liu et al. (2012), and flags gaps in non-breast applications. DeepScan's 7-step chain verifies IHC correlations using CoVe on Albergaria et al. (2009) vs. Hennessy et al. (2009). Theorizer generates hypotheses on GATA3-FOXA1 interactions in metastasis from Theodorou et al. (2012).
Frequently Asked Questions
What defines GATA3 as a prognostic marker in metastatic carcinoma?
GATA3 is defined by immunohistochemical positivity correlating with survival in breast metastases, high in 92% of breast carcinomas (Liu et al., 2012).
What methods assess GATA3 expression?
Immunohistochemistry on tumor tissues with scoring for nuclear positivity, as in Liu et al. (2012) evaluating 1,110 carcinomas.
What are key papers on GATA3 prognosis?
Hennessy et al. (2009, 853 citations) on metaplastic breast cancer; Albergaria et al. (2009, 158 citations) on hormone-negative tumors.
What open problems exist?
Standardizing IHC cutoffs across carcinoma types and validating in non-breast metastases (Liu et al., 2012; Park et al., 2022).
Research Metastasis and carcinoma case studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching GATA3 as Prognostic Marker in Metastatic Carcinoma with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers